Hellenic Exchanges - Athens Stock Exchange Valuation
Is EXAE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EXAE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EXAE (€4.12) is trading above our estimate of fair value (€1.47)
Significantly Below Fair Value: EXAE is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EXAE?
Key metric: As EXAE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is EXAE's PE Ratio? | |
|---|---|
| PE Ratio | 15.1x |
| Earnings | €15.81m |
| Market Cap | €245.86m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.4x |
| Enterprise Value/EBITDA | 9.2x |
| PEG Ratio | 1.4x |
Price to Earnings Ratio vs Peers
How does EXAE's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 12.8x | ||
BLEKEDROS Ble Kedros REIC | 16.9x | n/a | €150.5m |
PVMEZZ Phoenix Vega Mezz | 1.9x | n/a | €114.3m |
EX Euroxx Securities | 29.9x | n/a | €63.9m |
TELL Bank of Greece | 2.6x | n/a | €264.2m |
EXAE Hellenic Exchanges - Athens Stock Exchange | 15.1x | 10.7% | €245.9m |
Price-To-Earnings vs Peers: EXAE is expensive based on its Price-To-Earnings Ratio (15.1x) compared to the peer average (12.8x).
Price to Earnings Ratio vs Industry
How does EXAE's PE Ratio compare vs other companies in the European Capital Markets Industry?
| 17 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 17 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: EXAE is expensive based on its Price-To-Earnings Ratio (15.1x) compared to the European Capital Markets industry average (13.1x).
Price to Earnings Ratio vs Fair Ratio
What is EXAE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 15.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EXAE's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €4.12 | €6.93 +68.4% | 11.4% | €8.60 | €6.10 | n/a | 7 |
| Nov ’25 | €4.25 | €6.69 +57.3% | 16.3% | €8.60 | €4.80 | n/a | 7 |
| Oct ’25 | €4.54 | €6.69 +47.4% | 16.3% | €8.60 | €4.80 | n/a | 7 |
| Sep ’25 | €4.52 | €6.69 +47.9% | 16.3% | €8.60 | €4.80 | n/a | 7 |
| Aug ’25 | €4.78 | €6.69 +39.9% | 16.3% | €8.60 | €4.80 | n/a | 7 |
| Jul ’25 | €4.90 | €6.66 +35.9% | 16.5% | €8.60 | €4.80 | n/a | 7 |
| Jun ’25 | €4.91 | €6.66 +35.6% | 16.5% | €8.60 | €4.80 | n/a | 7 |
| May ’25 | €5.16 | €6.63 +28.6% | 17.8% | €8.60 | €4.80 | n/a | 6 |
| Apr ’25 | €5.46 | €6.62 +21.2% | 18.0% | €8.60 | €4.80 | n/a | 6 |
| Mar ’25 | €5.59 | €6.44 +15.2% | 19.1% | €8.60 | €4.80 | n/a | 5 |
| Feb ’25 | €5.63 | €5.90 +4.8% | 11.1% | €6.40 | €4.80 | n/a | 4 |
| Jan ’25 | €5.30 | €5.80 +9.4% | 10.3% | €6.40 | €4.80 | n/a | 4 |
| Dec ’24 | €5.31 | €6.13 +15.5% | 3.1% | €6.40 | €6.00 | n/a | 3 |
| Nov ’24 | €4.82 | €6.20 +28.6% | 2.6% | €6.40 | €6.00 | €4.25 | 3 |
| Oct ’24 | €4.79 | €5.85 +22.1% | 10.6% | €6.40 | €4.80 | €4.54 | 4 |
| Sep ’24 | €5.20 | €5.85 +12.5% | 10.6% | €6.40 | €4.80 | €4.52 | 4 |
| Aug ’24 | €5.56 | €5.70 +2.5% | 10.4% | €6.40 | €4.80 | €4.78 | 4 |
| Jul ’24 | €5.15 | €5.32 +3.3% | 8.4% | €6.00 | €4.80 | €4.90 | 5 |
| Jun ’24 | €4.91 | €4.85 -1.2% | 6.6% | €5.30 | €4.40 | €4.91 | 4 |
| May ’24 | €4.01 | €4.74 +18.2% | 7.6% | €5.30 | €4.30 | €5.16 | 5 |
| Apr ’24 | €3.93 | €4.74 +20.8% | 7.6% | €5.30 | €4.30 | €5.46 | 5 |
| Mar ’24 | €4.33 | €4.60 +6.4% | 5.5% | €4.90 | €4.30 | €5.59 | 4 |
| Feb ’24 | €3.95 | €4.60 +16.6% | 5.5% | €4.90 | €4.30 | €5.63 | 4 |
| Jan ’24 | €3.10 | €4.67 +50.5% | 5.6% | €4.90 | €4.30 | €5.30 | 3 |
| Dec ’23 | €3.16 | €4.67 +47.7% | 5.6% | €4.90 | €4.30 | €5.31 | 3 |
| Nov ’23 | €3.18 | €4.67 +46.8% | 5.6% | €4.90 | €4.30 | €4.82 | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.